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Background: Aberrated activation of cMet in gastric cancer contributes to tumor growth, angiogenesis and
metastasis. cMet-overexpressing gastric cancer has a poor prognosis because of high tumor metastasis and limited
therapeutic options. Luteolin is a common dietary flavonoid with antitumor properties. However, the antitumor
effect of luteolin on cMet-overexpressing gastric cancer remain unclear.
Methods: Two cMet-overexpressing patient-derived human tumor xenograft (PDTX) models of gastric cancer were
established, and treated with luteolin or vehicle to evaluate the antitumor effects of luteolin. Tumor specimens were
subjected to H&E staining and immunohistochemistry. MKN45 and SGC7901 cells that show high cMet expression
were treated with varying concentrations of luteolin and evaluated by western blot, cell viability, apoptosis,
migration, and invasion assays.
Results: Luteolin inhibited the tumor growth in cMet-overexpressing PDTX models. Immunohistochemistry
demonstrated that expression of cMet, MMP9 and Ki-67 were significantly down-regulated. Luteolin inhibited
proliferation, promoted apoptosis and reduced the invasiveness of MKN45 and SGC7901 cells. Western blot
revealed that luteolin promoted the activation of apoptosis-related proteins, caspase-3 and PARP-1, and
down-regulated the invasion-associated protein, MMP9. Further studies demonstrated that luteolin decreased
the expression and phosphorylation of cMet, and downstream phosphorylation of Akt and ERK. In addition,
luteolin down-regulated phosphorylated Akt independently of cMet. Blocking Akt and/or ERK with the PI3K
inhibitor, LY294002, or the ERK inhibitor, PD98059, induced down-regulation of MMP9 and up-regulation of
cleaved caspase-3 and PARP-1, resembling the effects of luteolin.
Conclusions: Our findings ,for the first time, demonstrate that luteolin exerts marked antitumor effects in
cMet-overexpressing PDTX models of gastric cancer, through a mechanism likely involving cMet/Akt/ERK signaling.
These findings indicate that luteolin may act as a potential therapeutic option for cMet-overexpressing gastric cancer.
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Gastric cancer (GC) is the one of the most commonly
diagnosed cancers, and the second leading cause of can-
cer deaths worldwide [1,2]. Despite improvements in
surgery and chemotherapy, the prognosis of advanced
gastric cancer remains poor. cMet is a member of the
receptor tyrosine kinase family, and the major signaling
cascades activated by cMet include the phosphoinosi-
tide 3-kinase (PI3K)-Akt and Ras-mitogen-activated
protein kinase (MAPK) pathways that are associated
with tumor survival, growth, angiogenesis and metasta-
sis [3,4]. cMet-overexpressing gastric cancer, which ac-
counts for approximately 40% of all gastric cancer cases,
has been shown to correlate with an advanced disease
stage and poor prognosis [5-7]. Previous studies of gastric
cancer have revealed that co-expression of hepatocyte
growth factor (HGF) and c-Met has the potential to
promote peritoneal dissemination, and that a high level
of c-Met expression is involved in the mechanisms of
liver metastasis [3,8]. Moreover, cMet-overexpressing
gastric cancer cells can acquire resistance to therapy
targeted against the HER family, such as epidermal
growth factor receptor-2 (Her2) and the epidermal
growth factor receptor (EGFR) [9,10]. cMet-overexpressing
gastric cancer possesses a more aggressive cancer pheno-
type and has a poorer prognosis; therefore, optimizing
drugs for the treatment of this type of gastric cancer is
crucial.
Luteolin (3′,4′,5,7-tetrahydroxyflavone) is one of the
most common flavonoids found in various types of vege-
tables and fruits, such as celery, green peppers, carrots
and olive oil. Luteolin shows strong anti-proliferative ac-
tivity against a diversity of cancer cells, including breast,
prostate and gastric cancers [11-13].
Previous studies have indicated that luteolin exerts its
anti-tumor actions by affecting numerous biochemical
pathways critical for the regulation of cell survival, apop-
tosis, angiogenesis and metastasis, including PI3K/Akt,
nuclear factor-κB (NF-κB), MAPKs, matrix metallopro-
teinases (MMPs) and E-cadherin [14-18]. In addition,
recent experimental studies have shown that luteolin
can suppress HGF-induced c-Met phosphorylation in
HepG2 cells, and inhibit the expression of cMet in
DU145 prostate cancer cells [8,19]. Although it has been
suggested that luteolin possesses strong antitumor charac-
teristics, an effect on cMet-overexpressing gastric cancer
cells has yet to be clearly demonstrated.
One of the main obstacles hampering progress in
oncological drug research is a lack of appropriate pre-
clinical models. Patient-derived human tumor xenograft
(PDTX) models, which closely retain the histopatho-
logic, genetic and phenotypic features of the original
clinical cancer, offer a powerful tool for the study of
tumor biology and the evaluation of anticancer drugs.Recently, we established PDTX models of colon carcin-
oma, and successfully evaluated a novel molecular drug
[20,21]. In the present study, we evaluated the antitumor
efficacy of luteolin in cMet-overexpressing PDTX models
as well as in gastric cancer cell lines.
Materials and methods
Reagents and drugs
The antibodies against cMet, Akt and ERK, and
phosphorylation-specific antibodies against phospho-
Met (Y1234/1235), Akt (Ser308 and Ser473) and ERK
(Thr202/Tyr204) were purchased from Cell Signaling
Technology (Danvers, MA, USA). The antibodies against
Her2, MMP9, Ki-67, caspase-3, cleaved caspase-3, poly
(ADP-ribose) polymerase (PARP), cleaved PARP and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) were
obtained from Epitomics, Inc. (Burlingame, CA, USA).
Horseradish peroxidase-conjugated secondary antibodies
were sourced from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). Luteolin was purchased from Sigma-
Aldrich (St. Louis, MO, USA). LY294002 and PD98059
were obtained from Selleck Chemicals LLC (Houston,
CA, USA).
Establishment of xenografts and treatment protocol
Four-to-six-week-old female BALB/c nude mice, pur-
chased from Shanghai Slac Laboratory Animal Corporation
(Shanghai, China), were housed with regular 12-hour light/
12-hour dark cycles for at least three days before use. Ani-
mal care was carried out in accordance with the Principles
of Laboratory Animal Care (NIH publication #85-23, re-
vised in 1985). All experimental protocols conducted in the
present study were approved by the Institutional Animal
Care and Use Committee of Zhejiang University (approval
ID: SYXK[ZHE]2005-0072). Tumor specimens were ob-
tained at initial surgery, after the patient had provided
written informed consent. The patient had not received
chemotherapy or radiation therapy before surgery. The
tumors were diagnosed as poorly differentiated adeno-
carcinoma, according to WHO criteria (Additional file 1:
Table S1). The PDTX xenograft models of gastric carcin-
oma were established as previously described [21,22].
Briefly, the tumors were implanted subcutaneously into
the flanks of mice, under anesthesia with isoflurane.
Growth of the xenografts was monitored at least twice-
weekly by vernier caliper measurement of the length
(a) and width (b) of the tumor. After reaching a volume
of about 1500 mm3, the tumor was removed for serial
transplantation.
Xenografts from the third generation (the second
mouse-to-mouse passage) were used for the experiments,
once the tumor volume had reached about 100 mm3.
Mice with third generation xenografts were randomized
into two groups (5–6 mice per group), to receive either
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by intraperitoneal (ip) injection daily for 1 month. Mouse
weight and tumor volume were measured daily(5 mice per
group). Tumor volume was calculated as (length ×width2)/
2. Relative tumor growth inhibition (TGI) was calculated
using the formula: TGI = 1 - T/C, where T/C represents
the relative tumor growth of luteolin-treated mice divided
by the relative tumor growth of control (DMSO-treated)
mice.
Histology and immunohistochemistry
Tumor-bearing mice were anesthetized and the tumors
harvested. Tumor specimens were then fixed in 4% para-
formaldehyde for 12 hours and embedded in paraffin.
Five-micrometer sections were cut, dewaxed, rehydrated,
and stained with hematoxylin and eosin (H&E) as described
previously [23]. For immunohistochemical staining, five-
micrometer sections were cut, dewaxed, rehydrated, and
subjected to antigen retrieval. After quenching endogenous
peroxidase activity and blocking nonspecific binding sites,
the sections were incubated with primary antibodies against
cMet (1:100), HER2 (1:100), MMP9 (1:200) and Ki-67
(1:500) at 4°C for 12 hours. This was followed by a 30-min
incubation with secondary antibody. Immunohistochemis-
try was performed using the streptavidin-biotin peroxidase
complex method (Lab Vision, Fremont, CA, USA). The
sections were observed using an optical microscope (Nikon,
Tokyo Japan; 200×).
The expression of cMet was determined according to
HercepTest guidelines, as follows: no membrane staining
or membrane staining in <10% of tumor cells, a score of 0;
faint/barely perceptible partial membrane staining in >10%
of tumor cells, a score of 1+; weak-to-moderate staining
of the entire membrane in >10% of tumor cells, a score of
2+; and strong staining of the entire membrane in >10%
of tumor cells, a score of 3+. Scores of 0 or 1+ were con-
sidered as negative for MET overexpression, and scores of
2+ or 3+ were considered as positive [5]. For MMP9
assessment, we analyzed the staining intensity and the
percentage of stained tumor cells. Staining intensity was
scored as 0 (none), 1 (weak), 2 (moderate), and 3+
(strong), and the percentage was scored as 0% = 0
points, ≤25% = 1 point, 26 to 50% = 2 points, and ≥50% =
3 points. We calculated the final score by multiplying the
respective scores. For Ki-67 assessment, one hundred cells
were randomly selected and counted from five representa-
tive fields of each section, the percentage of stained tumor
cells were calculated. All immunohistochemical slides
were reviewed by two independent pathologists.
Western blotting
Briefly, lysates for immunoblotting were prepared by
adding lysis buffer (50 mM Tris–HCl [pH 7.4], 1%
Nonidet P-40, 0.5% sodium deoxycholate, 150 mMNaCl, 0.02% sodium azide, and 0.1% SDS) containing
protease and phosphatase inhibitors (Sigma-Aldrich,
St. Louis, MO, USA) to cells or tumor tissue homoge-
nized in liquid nitrogen. Appropriate cell and tissue
protein extracts were fractionated by SDS-PAGE and
electro-transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Billerica, MA, USA). After block-
ing for 1 h at room temperature in 5% milk in TBS-T
(10 mM Tris–HCl [pH 7.5], 0.5 M NaCl, and 0.05% [w/v]
Tween 20), the membranes were incubated overnight at
4°C with appropriate primary antibodies. The next day,
the membranes were washed and then incubated with
suitable peroxidase-conjugated secondary antibodies for
1 h at room temperature. After washing three times with
TBS, the blot was soaked for 1 min in ECL™ chemilumin-
escent detection reagents (Millipore, Billerica, MA, USA).
The membranes were then placed between two sheets of
plastic wrap and exposed to film (Kodak, Rochester, NY,
USA) for 30 s in a darkroom. To show equal protein
loading, the blots were stripped and reprobed for
peroxidase-conjugated GAPDH antibody. The experiments
were repeated at least three times.
Cell culture
MKN45, MKN28, BGC823, AGS and SGC7901 cells were
obtained from the Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). These cell lines
were passaged for fewer than 6 months after resuscitation.
Cell lines were routinely cultured at 37°C in the presence
of 5% CO2 in RPMI 1640 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% FBS (Hyclone; GE Healthcare,
Little Chalfont, UK).
Cell viability assay
The effect of luteolin on cell viability was assessed using
the methyl-thiazolyl-tetrazolium (MTT) assay. In brief,
cells were seeded into 96-well plates at 5000 cells per
well. After overnight incubation, the cells were treated
with DMSO vehicle (1 μL/mL) and varying concentra-
tions of luteolin (20, 40 and 80 μM in DMSO) for 24, 48
and 72 h. For measurement of cell growth, each well
was incubated with MTT (0.5 mg/mL) for 4 h at 37°C.
Afterwards, the supernatant was removed and the
formazan crystals dissolved in 200 μL DMSO at room
temperature. Absorbance of the solution was then mea-
sured at a 490-nm wavelength using an MRX II absorb-
ance reader (Dynex Technologies, Chantilly, VA, USA).
Cell apoptosis assay
The apoptosis-inducing effect of luteolin was investigated
using annexin V-fluorescein isothiocyanate (FITC) and
flow cytometry. Cells grown in six-well plates were treated
with varying concentrations of luteolin (0–80 μM in
DMSO) for 24 h. The cells were then harvested, washed
Figure 1 Histological and molecular characterization of the
PDTX models of gastric cancer. a, b: H&E staining. c, d:
Immunohistochemical staining for cMet. e, f: Immunohistochemical
staining for Her2. Immunodetectable protein is indicated by
brown staining; nuclei are counterstained blue. Original
magnification, ×200.
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tration of 1 × 106 cells/mL, and mixed with 5 μL annexin
V-FITC and 5 μL propidium iodide for 15 min. Stained
cells were analyzed using an FC500 flow cytometer and
CXP software (Beckman Coulter, Fullerton, CA, USA).
The percentage of apoptotic cells was determined by the
CXP software.
In vitro migration and invasion assay
Cell migration and invasion assays were carried out as
described previously [24]. For these assays, the cells were
pre-starved in serum-free medium for 12 h. According
to the protocol provided by the manufacturer (Millipore,
Billerica, MA, USA), 900 μL of medium with 10% FBS
was added into the wells of a 24-well plate, and 8-mm
pore transwell inserts were plated into these wells for 1-h
rehydration at 37°C . For the cell invasion assay, the upper
chamber of a transwell was coated with Matrigel (BD
Biosciences, San Jose, CA, USA) for 30 min at 37°C be-
fore rehydration. Starved cells were resuspended in
serum-free medium at 3 × 105 cells per well for the inva-
sion assay, and 1 × 105 cells per well for the migration
assay, and seeded into the upper chamber. Both the
upper chamber and lower chamber contained varying
concentrations of luteolin (0–20 μM in DMSO). After
incubation for 24 h at 37°C, cells on the upper side of
the membrane were removed with cotton swabs. The
cells on the lower surface of the filters were fixed with
methanol and stained with 0.1% crystal violet. The num-
bers of migrated or invaded cells were then counted
from 5 random fields under × 200 magnification.
Statistical analysis
All values were tested for normal distribution and are
expressed as mean ± SD. Differences between groups were
assessed using the Student’s t-test (two-tailed). P < 0.05
was taken to indicate statistical significance. Statistical cal-
culations were performed using SPSS 16.0 software (IBM
Corporation, Armonk, NY, USA).
Results
Histological and molecular characterization of the PDTX
models of gastric cancer
The PDTX models of gastric cancer were successfully
established, with histological examinations of H&E sec-
tions from the third generation xenografts of both
Met-GC1 and Met-GC2 showing poorly differentiated
adenocarcinoma consistent with the original clinical
cancer (Figure 1a, b). We had previously ascertained
that PDTX xenografts could retain the histopathologic
and molecular characteristics of the original clinical can-
cer [20,21]. The expressions of cMet and HER2 were eval-
uated, since trastuzumab has been recommended as a
treatment for patients with Her2-overexpressing gastriccancer. Immunohistochemical analysis showed that both
the Met-GC1 and Met-GC2 xenograft models were posi-
tive for cMet overexpression (+++) but negative for Her2
overexpression (−) (Figure 1c–f ).
Luteolin inhibits tumor growth in PDTX models of gastric
cancer
We next examined the effects of luteolin on growth of
the PDTX models of gastric cancer. Luteolin significantly
inhibited tumor growth, compared with the DMSO ve-
hicle control, in both the cMet-GC1 and cMet-GC2
models (Figure 2a). No obvious differences were observed
between the Met-GC1 and Met-GC2 models in the rate of
tumor inhibition by luteolin (Figure 2b). No apparent tox-
icity or weight loss was observed with luteolin administra-
tion during the experimental period (Figure 2c).
Effects of luteolin administration on the expressions of
cMet, p-cMet, Akt, p-Akt, ERK, p-ERK, MMP9 and Ki-67
in PDTX models of gastric cancer cMet-overexpression in
gastric cancer is accompanied by abnormal activation of
cMet signaling that contributes to tumor survival, growth
and metastasis. We conducted immunohistochemical and
Western blot analysis of the cMet signaling pathway. Im-
munohistochemistry demonstrated that the expression of
cMet protein was significantly decreased in the luteolin-
treated groups. The expressions of MMP9, an indicator of
potential metastatic capability, and Ki-67, a proliferation
maker, were also greatly decreased in the luteolin-treated
Figure 2 Luteolin inhibits tumor growth in cMet-overexpressing PDTX models of gastric cancer. a: Changes in tumor volume in Met-GC1
and Met-GC2 models of gastric cancer treated for 30 days with luteolin (10 mg/kg ip daily) or DMSO (as a vehicle control). b: Tumor growth
inhibition rates in Met-GC1 and Met-GC2 models of gastric cancer treated with luteolin (10 mg/kg ip daily). c: Changes in mouse body weight in
Met-GC1 and Met-GC2 models of gastric cancer treated for 30 days with luteolin (10 mg/kg ip daily) or DMSO (as a vehicle control). Data are
presented as the mean ± SD. *P < 0.05 (Student’s t-test).
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blot analysis revealed down-regulated expression of cMet
and phosphorylated cMet in the luteolin-treated groups.
Only slight inhibition of phosphorylated ERK and Akt was
observed in the luteolin-treated groups (Figure 4).
Luteolin inhibits proliferation and induces apoptosis of
MKN45 and SGC7901 cells.To further investigate the
possible mechanisms involved in the anti-tumor effects
of luteolin in cMet-overexpressing gastric cancer, we
first examined cMet expression in a series of gastric can-
cer cells, including MKN45, MKN28, AGS, BGC823 and
SGC7901 cells. On the basis of these data, MKN45 and
SGC7901 cells, which showed high expression of cMet,
were selected for further study (Figure 5a). The MTT
assay demonstrated that luteolin markedly inhibited the
growth of MKN45 and SGC7901 gastric cancer cells in a
concentration- and time-dependent manner (Figure 5b).
To determine whether luteolin-induced cell death in
MKN45 and SGC7901 cells was via an induction of
apoptosis, we evaluated cell apoptosis using flow cytom-
etry analysis, with propidium iodide and annexin-V
staining. The data indicated that luteolin administration
caused apoptosis in a concentration-dependent manner
(Figure 5c). The percentage of apoptotic MKN45 and
SGC7901 cells increased from 8.0% and 6.9%, respect-
ively, at 20 μM luteolin to 23.7% and 20.2%, respectively,
at 80 μM luteolin (Figure 5d). Western blot analysis
revealed increased expression of cleaved caspase-3 and
cleaved PARP (indicators of apoptosis) (Figure 5e).Luteolin inhibits the migration and invasion of
MKN45 and SGC7901 cells.Low concentrations of
luteolin (0–20 μM) administered for 24 h did not affect
the viability of MKN45 and SGC7901 cells. However,
as shown in Figure 6b, administration of low concentra-
tions of luteolin resulted in a concentration-dependent in-
hibition of migration and invasion of both MKN45 and
SCG7901 cells. Since MMP9 expression was found to be
decreased in Met-GC1 and Met-GC2 models treated with
luteolin (see above), the expression of MMP9 was also
evaluated in MKN45 and SGC7901 cells treated with
luteolin for 24 h. As shown in Figure 6c, luteolin also
down-regulated MMP9 expression in both these gastric
cancer cell lines. As MMP9 plays an important role in
tumor invasion, the down-regulation of MMP9 may be in-
volved in the inhibition of invasiveness by luteolin.
Luteolin down-regulates cMet/Akt/ERK signaling in MKN45
and SGC7901 cells
To further examine the involvement of the cMet signaling
pathway in the anti-proliferative and anti-invasive actions
of luteolin, we treated cells with various concentrations of
luteolin (0–80 μM) for 24 h, and performed immuno-
blotting assays. As shown in Figure 7a, luteolin caused
concentration-dependent reductions in total cMet protein
and phosphorylated cMet levels in MKN45 and SGC7901
cells. Phosphorylated Akt and ERK, downstream signaling
molecules of cMet, were also down-regulated. At a
luteolin concentration of 20 μM, phosphorylated Akt
Figure 3 Effects of luteolin administration on the expressions of cMet, Akt, ERK, MMP9 and Ki-67 in PDTX models of gastric cancer.
H&E staining and immunohistochemistry were undertaken after administration for 30 days of either luteolin or DMSO (as a vehicle control).
Immunodetectable protein is indicated by brown staining; nuclei are counterstained blue. Original magnification, ×200.
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change in the phosphorylation of cMet (Figure 7a),
indicting that Akt down-regulation preceded cMet
down-regulation. To examine this hypothesis, Western
blot analysis was carried out in MKN45 cells treated
with luteolin for 6 h, with reference to a previous study
[19]. As shown in Figure 7b, at a concentration of 40 μM,
luteolin significantly suppressed phosphorylated Akt but
did not affect cMet phosphorylation. Furthermore, when
AGS cells, which show low cMet expression, were treated
with various concentrations of luteolin (0–80 μM) for
24 h, Western blot assays showed that luteolin significantly
suppressed phosphorylated Akt with no obvious change in
the phosphorylation of cMet and ERK (Figure 7c). Hence,
the down-regulation of phosphorylated Akt appeared to be
independent of cMet status, even occurring ahead of
the change in cMet. Therefore, we further investigated
whether the decrease in phosphorylated Akt led to the
down-regulation of phosphorylated cMet. To do this, we
used LY294002, a PI3K inhibitor, to determine whether
prolonged inhibition of Akt phosphorylation resulted in a
reduction in cMet phosphorylation. The data revealed that
the administration of LY294002 to MKN45 cells for 24 h
was without effect on cMet phosphorylation, despite an
inhibition of phosphorylated Akt (Figure 7d). Further
consideration of the data presented in Figure 7a, b, c
suggested that the decrease in cMet expression mirrored
the reduction in cMet phosphorylation. Thus, it was likelythat the reduction in phosphorylated cMet was the result
of a down-regulation in cMet expression. Together, the
data indicate that luteolin could down-regulate total cMet
and phosphorylated cMet, and inhibit the activity of
downstream Akt and ERK signaling.
Involvement of Akt and ERK in the regulation of caspase-3,
PARP-1 and MMP9
We next assessed the contributions of Akt and ERK in
the effects of luteolin to induce apoptosis and inhibit
invasiveness. MKN45 cells were harvested for Western
blot analysis after exposure for 24 h to either the PI3K
inhibitor, LY294002 (20 μM), the ERK inhibitor, PD98059
(50 μM), luteolin (40 μM), or the combination of
LY294002 and PD98059. As shown in Figure 7e, the
administration of LY294002 or PD98059 inhibited p-Akt
or p-ERK, respectively. Combination treatment with
LY294002 and PD98059 suppressed p-Akt and p-ERK
simultaneously, similar to the effect of luteolin. Further-
more, the apoptosis-related proteins, cleaved caspase-3
and cleaved PARP-1, were both up-regulated in all four
treatment groups (LY294002, PD98059, luteolin, or
LY294002 plus PD98059), while MMP9 was down-
regulated in all four treatment groups, and particularly
in the LY294002 plus PD98059 group. Thus, both
PD98059 and LY294002 were able to mimic the effects
of luteolin on the regulation of caspase-3, PARP-1 and
MMP9. Since caspase-3, PARP-1 and MMP9 are involved
Figure 4 Representative immunoblot data showing the
expressions of proteins in the cMet signaling pathway. Western
blotting was employed to probe for cMet, p-cMet, Akt, p-Akt, ERK
and p-ERK; GAPDH was used as a loading control.
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regulation of cMet/Akt/ERK is, at least in part, involved in
the effects of luteolin to promote apoptosis and inhibit
invasiveness.
Discussion
cMet-overexpressing gastric cancer is associated with ad-
vanced disease stage and poor prognosis [6,7]. The aggres-
sive nature of cMet-overexpressing gastric cancer and the
lack of effective therapeutic options make this cancer par-
ticularly clinically challenging, so it is crucial that new
therapies are identified. However, research in this area has
been hampered by a lack of clinically relevant experimen-
tal models. It is well established that PDTX models better
retain the histopathologic, genetic and phenotypic features
of the original tumor than conventional cell-implanted
xenografts [22]. Hence, PDTX models have been increas-
ingly used as a tool for the preclinical assessment of anti-
cancer drugs. Our group has previously established PDTX
models of colon carcinoma, and successfully evaluated a
novel VEGF-targeted agent [20,21].In this study, we evaluated the antitumor effects of
luteolin in cMet-overexpressing PDTX models of gastric
cancer. To our knowledge, this is the first study of luteo-
lin in PDTX models. Our results showed that luteolin
exerted a significant antitumor effect in these models of
gastric cancer. An in vitro study further revealed that
luteolin greatly inhibited the proliferative and invasive
activity of MKN45 and SGC7901 gastric cancer cells,
which highly expressed cMet. Immunohistochemical
data demonstrated that luteolin greatly reduced the ex-
pressions of cMet, MMP9 and ki-67 (Figure 3); consistent
with this, the in vitro study indicated that luteolin sig-
nificantly down-regulated cMet signaling and MMP9
(Figures 6, 7). Together, these data suggest that luteo-
lin may be a candidate therapeutic option for cMet-
overexpressing gastric cancer.
Hyperactivation of the cMet signaling pathway has been
frequently observed in cMet-overexpressing cancer, and
reported to be associated with tumor survival, growth,
angiogenesis and metastasis [3,4,7]. Previous studies have
indicated that luteolin exerts its anti-tumor activity by
affecting numerous biochemical pathways critical for the
regulation of cell survival, apoptosis, angiogenesis and me-
tastasis, including PI3K/Akt, NF-κB, MAPKs, MMPs and
E-cadherin [14-18]. Lee et al. demonstrated that luteolin
suppressed HGF-induced phosphorylation of c-Met in
human hepatoma HepG2 cells. Coleman et al. further re-
vealed that luteolin post-transcriptionally down-regulated
c-Met expression independently of proteosomal/lysosomal
degradation in DU145 prostate cancer cells. Recently, Wu
et al. reported that luteolin can induce apoptosis by up-
regulating miR-34a in gastric cancer cells [25]. Anyway,
further investigations were still needed to elucidate the
possible mechanisms of antitumor effects of luteolin in
gastric cancer. In the present study, we observed that
luteolin decreased the expression and phosphorylation
of cMet in both cMet-overexpressing gastric tumor tis-
sue and gastric cancer cells with high cMet expression
(Figures 3, 4, 7a). We further revealed that downstream
Akt and ERK signaling was also down-regulated in
MKN45 and SGC7901 cells. Interestingly, luteolin also
caused a down-regulation of Akt without affecting the
activity of cMet and ERK (Figure 7b, c), suggesting that
the inhibition of Akt by luteolin could be independent
of cMet. We also showed that luteolin-induced down-
regulation of phosphorylated Akt occurred ahead of
the effects on cMet. We then confirmed that prolonged
inhibition of phosphorylated Akt had no influence on
phosphorylated cMet (Figure 7c). Further analysis of
the results in Figure 7a, b, c suggested that the de-
crease in cMet expression mirrored the reduction in
cMet phosphorylation. This finding implies that luteo-
lin can down-regulate total cMet and phosphorylated
cMet, and inhibit downstream Akt and ERK signaling,
Figure 5 Luteolin inhibits proliferation of MKN45 and SGC7901 gastric cancer cells. a: Western blot analysis of cMet expression in a series
of gastric cancer cell lines, including MKN45, MKN28, AGS, BGC823 and SGC7901 cells. b: Assessment of cell proliferation and viability, using the
MTT assay, in MKN45 and SGC7901 cells treated with varying concentrations of luteolin (10–80 μM) or DMSO (1 μL/mL) for 24, 48 or 72 h.
c: Evaluation of cell apoptosis, using flow cytometry and propidium iodide/annexin-V staining, in MKN45 and SGC7901 cells treated with varying
concentrations of luteolin (10–80 μM) or DMSO (1 μL/mL) for 24 h. The gate setting distinguished between early apoptotic (bottom right), late
apoptotic (top right), living (bottom left) and necrotic (top left) cells. d: The percentage of total apoptotic MKN45 and SGC7901 cells for varying
concentrations of luteolin (20–80 μM) or DMSO (1 μL/mL), quantified from three independent experiments. e: Western blot analysis of cleaved
caspase-3 and cleaved PARP expression after treatment with luteolin for 24 h. Data are presented as the mean ± SD. The blots shown are
representative of those from at least three independent experiments.
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cMet.
Previous research in different cell types has demon-
strated that Akt and ERK signaling play a central role in
the regulation of cell survival, proliferation and metasta-
sis [26-28]. Activation of the Akt and ERK pathway iscommon in cMet-overexpressing cancer [4], and this
activity can lead to a prevention of apoptosis [29,30]. In
this study, we found that luteolin promoted the apop-
tosis of MKN45 and SGC7901 cells in a concentration-
dependent manner, with activation of caspase-3 and PARP
(Figure 5). As mentioned above, luteolin was able to
Figure 7 Effects of luteolin on cMet/Akt/ERK signaling pathways (a) Western blot analysis of MKN45 and SGC7901 cells treated with
varying concentrations of luteolin (0–80 μM) for 24 h. (b) Western blot analysis of MKN45 cells treated with varying concentrations of luteolin
(0–80 μM) for 6 h. (c) Western blot analysis of AGS cells treated with varying concentrations of luteolin (0–80 μM) for 24 h. (d) cMet/Akt/ERK
status in MKN45 cells incubated for 24 h with LY294002 (a PI3K inhibitor; 20 μM), luteolin (40 μM) or both. (e) Western blot analysis of the
possible involvement of Akt/ERK in cell apoptosis and invasiveness. MKN45 cells were incubated for 24 h with either LY294002 (20 μM), PD98059
(50 μM), luteolin (40 μM), or a combination of LY294002 and PD98059. GAPDH was used as a loading control. The blots shown are representative
of those from at least three independent experiments.
Figure 6 Inhibitory effects of luteolin on MKN45 and SGC7901 cell migration and invasion. (a) Representative images showing MKN45 and
SGC7901 cell migration and invasion. Cells were seeded in transwell plates, incubated with 0–20 μM luteolin for 24 h, and then fixed and stained
with 0.1% crystal violet. (b) Cells (blue in color) on the lower surface were counted in triplicate, in three independent experiments, using a light
microscope. (c) MMP9 expression evaluated by Western blotting. Data are presented as the mean ± SD. Original magnification, ×200.
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ther observed that both PD98059 (an ERK inhibitor)
and LY294002 (an Akt inhibitor) could mimic the ef-
fects of luteolin on the activation of caspase-3 and
PARP-1. Previous investigations have also shown that
LY294002 or PD98059 could inhibit the growth of gastric
cancer cells and induce apoptosis [31-33]. Based on these
findings, we suggest that luteolin may promote apoptosis
partly via the down-regulation of phosphorylated Akt and
ERK.
MMP9, which can degrade collagen IV, plays an import-
ant role in cancer metastasis [34]. It has been reported
that MMP9 correlates with the invasion, metastasis and
angiogenesis of gastric cancer [33,35]. Several studies have
indicated that Akt and ERK regulate the expression of
MMPs [35,36]. Previous research has demonstrated that
the inhibition of Akt by LY294002 inhibited cancer cell
invasion and down-regulated MMP9 expression [37,38].
In addition, blocking the ERK1,2 pathway with a selective
chemical inhibitor, PD98059, could also down-regulate
MMP9 [39]. In the present study, we found that MMP9
was down-regulated in luteolin-treated tumor tissue and
cancer cells (Figures 3, 6c). Significant inhibitions of mi-
gration and invasion were also observed in the in vitro
study (Figure 6). To determine whether down-regulation
of phosphorylated Akt and ERK affected the expression of
MMP9, we treated MKN45 and AGS cells with LY294002
and/or PD98059: we observed that LY294002 or PD98059
could down-regulate MMP9, an effect similar to that of
luteolin (Figure 7d). Therefore, down-regulation of MMP9
may be involved in the inhibition of invasiveness by
luteolin.
Previous investigations have also reported that luteolin
can affect various receptors, such as EGFR, Her2 and
the androgen receptor [11,12,40]. In the present study,
we examined the cMet and HER2 status of the PDTX
models. The expression of EGFR was also examined, and
found to be Met-GC1 (−) and Met-GC2 (+) (immuno-
histochemistry; data not shown). However, the in vitro
study only examined the cMet status of MKN45 and
SGC7901 cells. In effect, there is a considerable amount
of HER2 and EGFR expression in MKN45 and SGC7901
cells, so we cannot exclude crosstalk effects from other
pathways. Moreover, we observed a decrease in phos-
phorylated Akt in luteolin-treated MKN45, SGC7901
and AGS cells. Although the present study has not defini-
tively established the underlying mechanisms, a possible
explanation is that luteolin can target Akt either directly
or through other pathways. Further studies are merited
to explore these possibilities. In addition, although we
successfully established two cMet-overexpressing gas-
tric cancer models in this study, we are now establishing
more PDTX models, since it is essential that clinically
reliable experimental systems are developed to facilitatethe discovery of novel therapeutic options for cMet-
overexpressing gastric cancer.
Conclusions
In summary, our findings strongly complement the
current knowledge concerning the treatment of cMet-
overexpressing gastric cancer. Our data demonstrate,
for the first time, that luteolin exerts marked antitumor ef-
fects in cMet-overexpressing PDTX models of gastric can-
cer, at least in part via down-regulation of cMet/Akt/ERK
signaling. These findings indicate that luteolin may act as
a potential therapeutic option for cMet-overexpressing
gastric cancer. Further study focusing on the role of luteo-
lin in cMet-overexpressing gastric cancer will provide
more detailed insights for the antitumor effects of luteolin
in the future.
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